- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Enzon Pharmaceuticals Inc
+ Add to WatchlistENZN:US
3.1700 USD 0.0100 0.31%As of 20:10:00 ET on 05/17/2013.
Snapshot for Enzon Pharmaceuticals Inc (ENZN)
| Open: | 3.2200 | Day's Range: | 3.1200 - 3.2200 | Volume: | 253,767 |
|---|---|---|---|---|---|
| Previous Close: | 3.1800 | 52wk Range: | 2.9401 - 5.3142 | 1-Yr Rtn: | -25.76% |
Key Statistics for ENZN
| Current P/E Ratio (ttm) | 15.8500 |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | 0.9714 |
| Earnings Per Share (ttm) | 0.2000 |
| Est. EPS (12/2013) | - |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 138.62 |
| Shares Outstanding (M) | 43.73 |
| 30 Day Average Volume | 434,484 |
| Price/Book (mrq) | 1.7441 |
| Price/Sale (ttm) | 3.4214 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend (USD) | 1.6000 |
| Last Dividend | 06/05/2013 |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/01/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for ENZN
Company Profile & Key Executives for ENZN
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes therapeutics to treat life-threatening diseases. The Company has developed several products, including PEG-INTRON. Enzon's product-focused strategy includes a drug development program that leverages its PEG modification and single-chain antibody (SCA) technologies.
| Ralph Del CampoChief Operating Officer | Andrew RackearChief Compliance Ofcr/Secy |
| Charles ConoverSenior VP:Research & Development | Timothy G DalyVP/Chief Acctg Ofcr/Controller |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
ENZN News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page